Medications

FDA links once-promising pain drugs to bone decay

Some of the world's largest drugmakers will face an uphill battle next week in their bid to revive a class of experimental arthritis drugs that have been sidelined by safety concerns for nearly two years.

Medications

With new generic rivals, Lipitor's sales halved

Sales of cholesterol blockbuster Lipitor plunged by half barely a week after the world's top-selling drug got its first U.S. generic competition, new data show.

Medications

FDA: studies do not tie Chantix to mental problems

(AP) -- Federal health officials said Monday that Pfizer's anti-smoking drug Chantix did not increase psychiatric problems like depression and suicidal thoughts in two studies, though the findings are not definitive.

Health

Soviet-era pill from Bulgaria helps smokers quit

(AP) -- A pill developed in Bulgaria during the Soviet era shows promise for helping millions of smokers cheaply and safely kick the habit, the first big study of it shows.

Oncology & Cancer

Antibody-guided drug works against acute lymphoblastic leukemia

An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be ...

Medications

Pfizer stops China vaccine sales as import license expires

Pfizer has stopped selling its Prevnar 7 pneumonia vaccine in China after its import license expired, but the U.S. drugmaker still intends to launch the world's most widely used vaccine, Prevnar 13, in that market.

Medications

Pfizer to pay $491M to resolve drug marketing case (Update)

The U.S. Justice Department said Tuesday that drugmaker Pfizer Inc. will pay almost $491 million to resolve an investigation into illegal marketing of the organ transplant drug Rapamune by a company Pfizer later acquired.

Medications

Pfizer 2Q mixed, maintains 2013 outlook

Pfizer's second-quarter net income more than quadrupled, helped by the sale of its animal health business. The world's second-largest drugmaker beat Wall Street's earnings expectations, though revenue continued to decline ...

page 3 from 6